ÝÃ §ç·ÛÆ ÒÇï¬·ÛÆ Þ Çï¬·ÛÆ w] º ... · $p iptu &mj-jmmz+bqbo, , Ô å ææ...

Medical Seminar / Evening Seminar / Morning Seminar

July 19 Thu Medical Seminar MeS-1 11:2012:10Room 2 21F

ChairIsamu Okamoto Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University

The treatment strategy of NSCLC focused on ICITony Mok Department of Clinical Oncology, The Chinese University of Hong Kong

Co-hostMSDKK. MSDTAIHOPHARMACEUTICALCO.,LTD.

MeS-2 11:2012:10Room 3 12FHall AChairKei Muro Aichi Cancer Center Hospital

Impact of primary tumor location on treatment strategy in patients with mCRC

Sebastian Stintzing Department of Medicine III, University Hospital, LMU Munich

Co-hostTakedaPharmaceuticalCompanyLimited

MeS-3 11:2012:10Room 4 12FHall BChairJunji Furuse Department of Medical Oncology, Kyorin University Faculty of Medicine

Chemotherapy of HCC for recent and futureAnthony Boutros El-Khoueiry Division of Medical Oncology, USC Norris Comprehensive

Cancer Center

Co-hostBayerYakuhin,Ltd.

2018 the Japanese Society of Medical Oncology Annual Meeting

61

MeS-4 11:2012:10Room 5 22F2AHow to choose the right first-line chemotherapy for metastatic colorectal cancer

ChairTakako Nakajima Department of Clinical Oncology, St.Marianna University School of Medicine

Japanese perspectivesYoshito Komatsu Department of Cancer Center, Hokkaido University Hospital Cancer Center

European perspectivesEric Van Cutsem Department of Digestive Oncology, The University of Leuven, Belgium

Co-hostTAIHOPHARMACEUTICALCO.,LTD.

MeS-5 11:2012:10Room 14 22F2BChairHidenori Inohara Department of Otolaryngology and Head and Neck Surgery, Osaka

University, Graduate School of Medicine

Whats the best treatment sequence in recurrent and metastatic HNSCC? Ushered in the new era of Immune-Oncology

Kevin Harrington The Royal Marsden Hospital The Institute of Cancer Research London, UK

Co-hostMerckSeronoCo.,Ltd

MeS-6 11:2012:10Room 6 23F3AExploring a treatment strategy for ALK+NSCLC based on evidence and practice use of ALK inhibitorsALK

ChairTerufumi Kato Department of Thoracic Oncology, Kanagawa Cancer Center

Detection and Prediction of ALK-TKI resistance, and the potential therapeutic strategies to overcome the resistanceALK

Ryohei Katayama Div. of Experimental Chemotherapy, Cancer Chemotherapy Center, JFCR

Clinical trial update regarding ALK+NSCLCShirish Madhav Gadgeel Department of Internal Medicine, Division of Hematology/Oncology,

University of Michigan, USA

Co-hostChugaiPharmaceuticalCo.,Ltd.


62

MeS-7 11:2012:10Room 7 23F3BChairShunji Takahashi Medical Oncology, The Cancer Institute Hospital Of JFCR

Treatment strategy for advanced MelanomaTatsuya Takenouchi Niigata Cancer Center Hospital Caroline Robert Gustave Roussy Cancer Campus Grand Paris

Co-hostBristol-MyersSquibbK.K. ONOPHARMACEUTICALCO.,LTD.

MeS-8 11:2012:10Room 8 B1FCancer genome profiling test for precision cancer medicine

ChairManabu Muto Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University

Experience of clinical cancer sequence

Takashi Kohno Division of Translational Genomics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center

TRExperience of expert panel How Expert panel make a medical decision about cancer genome profile

Yutaka Fujiwara Department of Experimental Therapeutics and Department of Thoracic Oncology, National Cancer Center Hospital

Co-hostSYSMEXCORPORATION

MeS-9 11:2012:10Room 9 B1FChairToru Watanabe Hamamatsu Oncology Center

Treatment strategy for HER2 positive MBC in EU/JapanJunji Tsurutani Department of Medical Oncology, Kindai University Faculty of Medicine Javier Corts Medical Oncology Department, Vall d'Hebron University Hospital



63

MeS-10 11:2012:10Room 10 1FChairAkihiko Gemma Department of Pulmonary Medicine and Oncology. Graduate School of

Medicine, Nippon Medical School

Past and future treatment strategy for EGFR mutation-positive non-small cell lung cancerEGFR

Yasushi Goto Department of Thoracic Oncology, National Cancer Center Hospital

Co-hostAstraZenecaK.K.

MeS-11 11:2012:10Room 11 3FWhat's AYA Patients' issue? From nurse and patient's point of viewAYA

ChairTakashi Seto Department of Clinical Oncology, Clinical Research Institute / Department of Thoracic Oncology National, Kyushu Cancer Center

Support to AYA Patients: From nursing point of view

Mitsue Maru Konan Womens University, International Nursing Development

Issues and current situation of AYA Patients: From patient point of viewAYA

Yohei Nishiguchi Cancer Parents General Incorporated Association


MeS-12 11:2012:10Room 12 5F501ChairKazuhito Yamamoto Aichi Cancer Center Hospital

r/r PTCL treatment strategyT

Takahiro Yamauchi Faculty of Medical Science, University of Fukui

Co-hostMUNDIPHARMAK.K.


64

MeS-13 11:2012:10Room 13 5F502ChairHiroshi Ishii Clinical Research and Trial Center, Chiba Cancer Center

Step One: Medical Treatments for Gastroenteropancreatic Neuroendocrine Tumor

Takuji Okusaka Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital

Co-hostTEIJINPHARMALIMITED

July 20 Fri Medical Seminar MeS-14 12:1013:00Room 2 21F

ChairYoichi Nakanishi Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University

Aiming for Cure Future prospects of treatment strategy for the patients with

unresectable Stage III NSCLC patients

Koichi Azuma Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine

Yuko Nakayama Department of Radiation Oncology, National Cancer Center Hospital


MeS-15 12:1013:00Room 3 12FHall AChairKazuhisa Takahashi Department of Respiratory Medicine, Juntendo University Faculty of

Medicine & Graduate School of Medicine

Treatment strategy for lung cancer in the era of upfront new combination therapy -ICI, TKI and cytotoxic chemotherapy and their combinationsCombination Therapy ICITKICytotoxic

Hidehito Horinouchi Department of Thoracic Oncology, National Cancer Center Hospital

Co-hostEliLillyJapanK.K.


65

MeS-16 12:1013:00Room 4 12FHall BChairAtsushi Sato Department of oncology, Hirosaki University

Gastlic Cancer

Ken Kato Nationcal Cancer Center Japan


MeS-17 12:1013:00Room 5 22F2AChairTakayuki Yoshino Department of Gastrointestinal Oncology, National Cancer Center

Hospital East

The current status and future direction of new drug development for mCRCJosep Tabernero Vall d' Hebron University Hospital


MeS-18 12:1013:00Room 14 22F2BChairHiroshi Kitamura Department of Urology, Graduate School of Medicine and

Pharmaceutical Sciences for Research, University of Toyama

Is Immuno-check point inhibitor the Breakthrough for Urothelial Cancer? Breakthrough

Nobuaki Matsubara Breast and Medical Oncology, National Cancer Center Hospital East

Co-hostMSDK.K. MSDTAIHOPHARMACEUTICALCO.,LTD.


66

MeS-19 12:1013:00Room 6 23F3AChairYasuhito Terui Hematology Oncology Department, Cancer Institute Hospital, Japanese

Foundation for Cancer Research

The chemotherapy management of malignant lymphoma a nurses viewpoint

Reiko Nagasaki Nursing Department, Cancer Institute Hospital, Japanese Foundation for Cancer Research

The chemotherapy management of malignant lymphoma a pharmacists viewpoint

Keiichi Azuma Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research

Co-hostChugaiPharmaceuticalCo.,Ltd. NipponShinyakuCo.,Ltd.

MeS-20 12:1013:00Room 7 23F3BChairHiroyuki Mano National Cancer Research Institute

Precision Medicine in the U.S.: Current Status and Future Perspective for Cancer Patients

Razelle Kurzrock University of California San Diego Moores Cancer Center


MeS-21 12:1013:00Room 8 B1FChairIsamu Okamoto Research Institute for Diseases of the Chest, Graduate School of Medical

Sciences, Kyushu University

Immunotherapy of advanced NSCLC: from 2nd line to near future.Maurice Prol Medical Oncology Department, Leon Berard Cancer Center, France


MeS-22 12:1013:00Room 9 B1FChairYoshinori Ito Breast Medical Oncology, Breast Oncology Center, Cancer Institute

Hospital, Japanese Foundation for Cancer Research

Optimizing outcomes in HR+/HER2 mBCSunil Verma Department of Oncology, University of Calgary

Co-hostPfizerJapanInc.


67

MeS-23 12:1013:00Room 10 1FChairTakeshi Kato Colorectal Division, National Hospital Organization Osaka National

Hospital

New Strategy for Metastatic Colorectal Cancer ~ Need to decide mCRC treatment according to patient's wishes ~ Shared Decision Making

Takeo Sato Department of Colorectal Surgery, Kitasato University School of Medicine


MeS-24 12:1013:00Room 11 3FChairShingo Matsumoto National Cancer Center Hospital East, Division of Thoracic

Oncology

Innovative application of liquid biopsy in oncology

Co-hostIQVIAServicesJapanK.K.IQVIA

MeS-25 12:1013:00Room 12 5F501ChairKensei Yamaguchi Gastroenterological Chemotherapy Department, The Cancer Institute

Hospital Of JFCR

Cancer immunotherapy Current status and Future perspective

Hiroya Taniguchi Department of Clinical Oncology, Aichi Cancer Center Hospital

Co-hostMSDK.K.MSD

MeS-26 12:1013:00Room 13 5F502ChairYukinori Kurokawa Department of Gastroenterological Surgery, Osaka University,

Graduate School of Medicine

Perioperative chemotherapy for advanced gastric cancer: Asian Perspectives

Yoon-Koo Kang Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine

Co-hostYakultHonshaCo.,Ltd.


68

Sadakatsu Ikeda Tokyo Medical Dental University, Cancer Center

July 21 Sat Medical Seminar MeS-27 12:5013:40Room 2 21F

ChairYuichiro Ohe Department of Thoracic Oncology, National Cancer Center Hospital

The New Treatment Option of Cancer Immunotherapy for Non-Small Cell Lung Cancer - Atezolizumab - --

Nobuyuki Yamamoto Division of Respiratory Medicine & Medical Oncology, Wakayama Medical University


MeS-28 12:5013:40Room 3 12FHall AChairTakayuki Yoshino Department of Gastroenterology and Gastrointestinal Oncology /

Clinical Research Coordinating Division, National Cancer Center

Hospital East

The latest trends of adjuvant chemotherapy for colon cancer from IDEA Collaboration, and the international consensus

Jean-Yves Douillard Chief Medical Officer, European Society of Medical Oncology ESMO


MeS-29 12:5013:40Room 4 12FHall BChairKensei Yamaguchi Department of Gastroenterological Chemotherapy, The Cancer

Institute Hospital of Japanese Foundation for Cancer Research

Management of Stage IV Gastric Cancer - Established Sequence and Novel Options

Florian Lordick University Cancer Center Leipzig UCCL, Germany



69

MeS-30 12:5013:40Room 5 22F2ATreatment of cancer associated coagulopathy

ChairChikashi Ishioka Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University

The purpose of DIC therapy in cancerDIC

Shin Takahashi Department of Medical Oncology, Tohoku University Hospital

Management of dissemminatied intravascular coagulation in cancerDIC

Kazuo Tamura General Medical Research Center, Faculty of Medicine, Fukuoka University

Co-hostAsahiKaseiPharmaCorporation

MeS-31 12:5013:40Room 14 22F2BChairNaoya Masumori Department of Urology, Sapporo Medical University School of

Medicine

Is RCT the strongest evidence? Conflicts between evidence and practiceRCTEvidencePractice

Nobuaki Matsubara Department of Breast and Medical Oncology, National Cancer Center Hospital East


MeS-32 12:5013:40Room 6 23F3AChairKoichi Takayama Department of Pulmonary Medicine, Graduate School of Medical

Science, Kyoto Prefectural University of Medicine

Global Strategies for the Treatment of EGFR Mutation Positive PatientJames Chih-Hsin Yang Graduate Institute of Oncology, College of Medicine, National Taiwan

University

Co-hostNipponBoehringerIngelheimCo.,Ltd.

MeS-33 12:5013:40Room 7 23F3BChairHirohiko Shibayama Department of Hematology and Oncology, Osaka University


Hodgkin Lymphoma

Andres Forero-Torres University of Alabama at Birmingham

Co-hostTakedaPharmaceuticalCompanyLimited


70

MeS-34 12:5013:40Room 8 B1FSecond-Line Strategies in the Treatment of Metastatic Colorectal Cancer

ChairNarikazu Boku Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital

Second line chemotherapy for metastatic colorectal cancer - translating clinical data into daily practice -

Hiroya Taniguchi Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East

To master second line chemotherapy for metastatic colorectal cancer Yukis opinion

Satoshi Yuki Department of Gastroenterology and Hepatology, Hokkaido University Hospital

Co-hostSanofiK.K. YakultHonshaCo.,Ltd.

MeS-35 12:5013:40Room 9 B1FChairKazuhisa Takahashi Graduate School of Medicine Respiratory Internal, Juntendo

University Hospital


MeS-36 12:5013:40Room 10 1FChairKoichi Goto Department of Thoracic Oncology, National Cancer Center Hospital East

Collaboration beyond specialty in lung cancer treatment - febrile neutropenia and oral care

Haruyasu Murakami Division of Thoracic Oncology, Shizuoka Cancer Center /Takashi Yurikusa Division of Dentistry and Oral Surgery, Shizuoka Cancer Center

Co-hostEliLillyJapanKK


71

Hidehito Horinouchi Department of Thoracic Oncology, National Cancer Center Hospital

MeS-37 12:5013:40Room 11 3FChairShinsuke Iida Department of Hematology & Oncology, Nagoya City University Graduate

School of Medical Sciences

Pathophysiology and management of bone disease in multiple myeloma

Masahiro Abe Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School

Co-hostDaiichiSankyoCo.,Ltd.

MeS-38 12:5013:40Room 12 5F501ChairYasuhiro Kodera Department of Gastroenterological Surgery, Nagoya University

Graduate School of Medicine 2

Tips for success in Precision medicine Pan-tumor approach & in-house preparationTips for success in Precision medicine

Hideaki Bando Department of Gastrointestinal Oncology, National Cancer Center Hospital East

Co-hostMSDK.K.MSD

MeS-39 12:5013:40Room 13 5F502ChairNoriyuki Katsumata Department of Medical Oncology, Nippon Medical School

Musashikosugi Hospital

Geriatric oncology and palliative care in the real small world

Koichi Kitagawa Division of Medical Oncology, Kobe Minimally Invasive Cancer Center

Co-hostHisamitsuPharmaceuticalCo.,Inc.KyowaHakkoKirinCo.,Ltd.


72

MeS-40 12:5013:40Room 15 5F504+505TAILORx

ChairHironobu Minami Medical Oncology / Hematology, Kobe University Graduate School Medicine

TAILORxSatoshi Morita Department of Biomedical Statistics and Bioinformatics, Kyoto University


OncotypeDXTatsuya Toyama Department of Breast Surgery, Nagoya City Univ Graduate School of Medical

Sciences

Co-hostGenomicHealthK.K.SRL,Inc.

July 19 Thu Evening Seminar ES-1 16:2017:10Room 3 12FHall A

Cancer Associated Thrombosis

ChairMitsuru Sasako Department of Surgery, Yodogawa Christian Hospital

Pathological condition of sudden death by acute pulmonary thromboembolism

Ayako Ro Department of Legal Medicine, St. Marianna University School of Medicine

Mechanism and management in cancer-associated thrombosis

Mikio Mukai Department of Medical Checkup, Osaka Prefectural Hospital Organization, Osaka International Cancer Institute

Co-hostDAIICHISANKYOCO.,LTD.


73

ES-2 16:2017:10Room412FHallBChairTakako Nakajima Department of Clinical Oncology, St. Marianna University School of

Medicine

RegorafenibformetastaticColorectalCancer-Uptodate-

Kentaro Yamazaki Division of Gastrointestinal Oncology, Shizuoka Cancer Center


ES-3 16:2017:10Room522F2AChairMakoto Tahara Department of Head and Neck Medical Oncology, National Cancer

Center Hospital East

Personalized immunotherapy in headand neck cancer

Robert Haddad Dana-Farber Cancer Institute


ES-4 16:2017:10Room623F3AChairKei Muro Department of Clinical Oncology and Outpatient Treatment Center, Aichi

Cancer Center Hospital

Gastriccancertreatmentupdate-Newinsightsintoclinicalpractice-update--

Narikazu Boku Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital



74

ES-5 16:2017:10Room 7 23F3BChairAkira Kawai Department of Musculoskeletal oncology and Rehabilitation, Rare Cancer

Center, National Caner Center Hospital

/

The role of anti-PD-L1 antibody in immuno-oncology the effacy of avelumab, first anti-PD-L1 antibody in Japan to Merkel cell caricinomaPD- L1

PD-L1Hiroyoshi Nishikawa Division of Cancer Immunology, Research Institute Exploratory

Oncology Research & Clinical Trial CenterEPOC National Cancer Center;

Department of Immunology, Nagoya University Graduate School of

Medicine TR

Yoshio Kiyohara Shizuoka Cancer Center, Dermatology Division

Co-hostMerckSeronoCo.,LtdPfizerJapanInc.

ES-6 16:2017:10Room 8 B1FChairKazuhiko Nakagawa Kindai University Faculty of Medicine

The Evolving Power of Immunotherapy -Transforming Outcomes in Advanced Lung Cancer-

Solange Peters Centre Hospitalier Universitaire Vaudois CHUV Oncology Department


ES-7 16:2017:10Room 9 B1FChairShigehira Saji Department of Medical Oncology, Fukushima Medical University

Predicting survival outcome and treatment benefit in HR+/HER2-negative metastatic breast cancer

Aleix Prat Head Medical Oncology Department, Hospital Clinic, University of Barcelona, Spain



75

ES-8 16:2017:10Room 10 1FChairHiroji Iwata Breast Oncology, Aichi Cancer Center Hospital

The Wonders of PFS/OS as the Primary endpoint in Clinical trialsPFS/OS

Satoshi Morita Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine

Tatsuya Toyama Department of Breast Surgery, Nagoya City University Graduate School of

Medical Sciences


ES-9 16:2017:10Room 11 3FChairTetsuya Mitsudomi Division of Theracic Surgery, Department Surgery, Kindai University

Faculty of Medicine

ALK+ Non-Small Cell Lung Cancer -The unsolved issues in Japanese practice-ALK--

Takashi Seto Department of Thoracic Oncology, National Kyushu Cancer Center

Co-hostNovartisPharmaK.K.

ES-10 16:2017:10Room 12 5F501ChairTakahiro Yamauchi Hematology and Oncology, First Department of Internal Medicine,

General Medicine, Faculty of Medical Science, University of Fukui 1

Great expectations in AMLCourtney D. DiNardo Department of Leukemia, Division of Cancer Medicine, MD Anderson

Cancer Center

Co-hostAbbVieGK

ES-11 16:2017:10Room 13 5F502ChairAkihito Tsuji Department of Clinical Oncology, Faculty of Medicine, Kagawa

University

Precision Medicine for Gastrointestinal CancerPrecision Medicine

Shigemi Matsumoto Department of Medical Oncology, Graduate School of Medicine, Kyoto University

Co-hostMOCHIDAPHARMACEUTICALCO.,LTD.PfizerJapanInc.


76

July 20 Fri Evening Seminar ES-12 17:1018:00Room 3 12FHall A

ChairChikashi Ishioka Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University

The importance of optimal drug sequencing in mCRC: Biological rationales for the patients benefit and future perspective

Co-hostMerckSeronoCo.,Ltd

ES-13 17:1018:00Room 4 12FHall BChairAkira Inoue Department of Palliative Medicine, Tohoku University School of Medicine

The newest opioid analgesic use Tapentadol thoughtfully

Kinomi Yomiya Division of Palliative care, Saitama Cancer Center

Co-hostMundipharmaK.K.


77

Sebastian Stintzing Department of Medicine III, University Hospital, LMU Munich

ES-14 17:1018:40Room 5 22F2AFor the Management of Skin Toxicity Associated with Immune Checkpoint Inhibitors and concomitant drugs A feedback from the Consensus meeting 2018 with Volunteer Medical Oncologists and Dermatologists --

ChairsNobuyuki Yamamoto Respiratory Medicine and Medical Oncology, Wakayama Medical University

Makoto Kawashima Tokyo Women's Medical University

Opening address: Skin Toxicity Associated with Immune Checkpoint Inhibitors and concomitant drugs. Case review of experience in Hyogo Cancer Center

Miyako Satouchi Department of Thoracic Oncology, Chemotherapy, Hyogo Cancer Center

Skin Toxicity Associated with Immune Checkpoint Inhibitors and concomitant drugs. Overview of symptoms

Yoshio Kiyohara Department of Dermatology, Shizuoka Cancer Center

Overview of Skin Toxicity with Immune Checkpoint Inhibitors

Naoya Yamazaki Department of Dermatologic Oncology, National Cancer Center Hospital

Panel Discussion Discussant / Tomohiro Nishina Department of Gastroenterology, National Hospital Organization Shikoku

Cancer CenterYuki Kogure Department of Pharmacy, National Hospital Organization Shikoku Cancer Center

Co-hostNon-profitOrganizationJASMINJASMIN


78

ES-15 17:1018:00Room 14 22F2BChairTaroh Satoh Department of Frontier Science for Cancer and Chemotherapy, Osaka

University Graduate School of Medicine

How to decipher New Gastric Cancer Treatment Guidelines : From major to minor changes

Eiji Oki Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University

Co-hostNipponkayakuCo.,Ltd.

ES-16 17:1018:00Room 6 23F3AChairShinsuke Iida Department of Hematology and Oncology, Nagoya City University

Graduate School of Medical Sciences

Treatment Strategy for Transplant Ineligible Newly Diagnosed Multiple Myeloma with Novel Agents

Hideto Tamura Department of Hematology, Nippon Medical School

Co-hostCelgeneK.K.

ES-17 17:1018:00Room 7 23F3BChairToshiyuki Sumi Department of Obstetrics and Gynecology, Osaka City University


Chemotherapy for Cervical Cancer Is CPT-11/NDP necessary? CPT-11/NDP

Nobuhiro Takeshima Department of Gynecological Oncology, Japanese Foundation For Cancer Research Cancer Institute Hospital

Co-hostNichi-IkoPharmaceuticalCo.,Ltd.


79

ES-18 17:1018:40Room 8 B1FThe positioning of Immunecheckpoint inhibitor and biomarkers in NSCLC

ChairTetsuya Mitsudomi Division of Thoracic Surgery Department of Surgery, Kindai University Faculty of Medicine

Implementation of genomic medicine in non-small cell lung cancer

Kazuto Nishio Department of Genome Biology, Kindai University Faculty of Medicine

Recent Progress for immunecheckpoint inhibitor in NSCLC

Kazuo Kasahara Respiratory Medicine, Kanazawa University Hospital

Co-hostMSDK.K. MSDTAIHOPHARMACEUTICALCO.,LTD.

ES-19 17:1018:00Room 9 B1FChairHironobu Minami Medical Oncology / Hematology, Kobe University Graduate School

Medicine

Current issues in outpatient chemotherapy

Hikaru Nakajima HematologyMedical Oncology, St. Luke's University Hospital, Lewis Katz School of Medicine at Temple University

HematologyMedical Oncology, St. Luke's University Hospital, Lewis Katz School of Medicine at Temple University

Hisashi Ishikura Department of Surgery, Division of Thoracic Surgery, Tokushima Red Cross Hospital

Masanori Toyoda Medical Oncology Hematology, Kobe University Graduate School

Medicine Yong-Il Kim Medical Oncology Yodogawa Christian Hospital

Co-hostKyowaHakkoKirinCo.,Ltd


80

ES-20 17:1018:00Room 11 3FChairEishi Baba Department of Comprehensive Clinical Oncology, Faculty of Medical

Sciences, Kyushu University

Treatment of Soft Tissue Sarcoma

Kan Yonemori Department of Breast and Medical Oncology Experimental Therapeutics, National Cancer Center

/


ES-21 17:1018:00Room 12 5F501How can we apply The Japanese Breast Cancer Society Guideline 2018 to clinical practice ?

2018ChairHiroji Iwata Aichi Cancer Center, Department of Breast Oncology

What is new? ; The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2018 edition

Junji Tsurutani Department of Medical Oncology, Kindai University Faculty of Medicine

How can we make the best use of molecular target drugs for treatment of postmenopausal hormone receptor positive advanced breast cancer?

Takahiro Nakayama Osaka International Cancer Institute Breast and Endocrine Surgery



81

ES-22 17:1018:00Room 13 5F502The Latest Updates and Clinical Practice in ALK/ROS1-positive lung cancerALK/ROS1

ChairYuichiro Ohe Division of Thoracic Oncology, National Cancer Center Hospital

Recent Updates in Oncogene-Driven Lung Cancer What's remaining issue?Driver Oncogene

Hiroaki Akamatsu Third Department of Internal Medicine, Wakayama Medical University

Optimal diagnostics and treatment of ROS1-positive lung cancerROS1

Toyoaki Hida Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya

Co-hostPfizerJapanInc. MerckSeronoCo.,Ltd.

July 20 Fri Morning Seminar MoS-1 7:308:20Room 4 12FHall B

ChairMiyako Satouchi Department of Thoracic Oncology, Hyogo Cancer Center

Points to note in genetic testing by Next Generation Sequencing for NSCLC in clinical practice and BRAF V600E mutation as therapeutic targetBRAF V600E

Yasuhiro Koh Department of Pulmonary Medicine and Medical Oncology, Wakayama Medical University


MoS-2 7:308:20Room 14 22F2BChairYuichi Ando Department of Clinical Oncology and Chemotherapy, Nagoya University

Hospital

Impact of TKIs on primary organs -Cardio-Renal Association for oncologists-

Mototsugu Oya Department of Urology, Keio University School of Medicine Mikio Mukai Department of Medical Checkup, Osaka International Cancer Institute



82

MoS-3 7:308:20Room 7 23F3BChairTakeshi Kuwata Department of Pathology and Clinical Laboratories, National Cancer

Hospital East

Future perspectives of liquid biopsy for cancer precision medicine

Kazuko Sakai Department of Genome Biology, Kindai University Faculty of Medicine

Co-hostRocheDiagnosticsK.K.

MoS-4 7:308:20Room 9 B1FChairAiko Okamoto The Jikei University School of Medicine

New prospective of platinum sensitive recurrent ovarian cancer

Richard T. Penson Harvard Medical SchoolMedical Gyn Onc Massachusetts General Hospital


MoS-5 7:308:20Room 11 3FChairFumio Imamura Department of Medical Oncology, Osaka International Cancer Institute

Benefit and risk for nivolumabBenefit and Risk

Hidetoshi Hayashi Department of Medical Oncology, Kindai University Faculty of Medicine

Co-hostONOPHARMACEUTICALCO.,LTD. Bristol-MyersSquibbK.K.


83

MoS-6 7:308:20Room 12 5F501Multidisciplinary approach to soft tissue sarcoma -Benefits and case study- --

ChairAkira Kawai Department of Musculosleletal Oncology and Rehabilitation, National Cancer Center Hospital

Benefits of the sarcoma center establishment and future perspectives of soft tissue sarcoma treatment

Satoshi Tsukushi Department of Orthopedic Surgery, Aichi Cancer Center Hospital

Involvement of medical oncologists in the multidisciplinary approach to soft tissue sarcoma

Masashi Ando Department of Clinical Oncology, Aichi Cancer Center Hospital


MoS-7 7:308:20Room 13 5F502Future treatment strategy for ER+ metastatic breast cancer New role of chemotherapyER

ChairYoshinori Ito Breast Medical Oncology, Breast Cancer Center, Cancer Institute Hospital

New trends of Endocrine resistance in ER+ Breast Cancer

Shin-ichi Hayashi Department of Molecular and Functional Dynamics, Tohoku University Graduate School of Medicine

Reconsidering the treatment strategy for ER+ Breast CancerER

Masato Takahashi Hokkaido Cancer Center

Co-hostEisaiCo.,Ltd.

MoS-13 7:308:20Room 2 21FChairSadakatsu Ikeda Tokyo Medical Dental University, Cancer Center

Clinical Validation of Guardant360 and Current clinical utility of liquid biopsyJustin Odegaard Guardant Health Inc.

Co-hostGuardantHealth,Inc.


84

July 21 Sat Morning Seminar MoS-8 7:308:20Room 5 22F2A

ChairMasatoshi Kudo Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine

Systemic Therapy for HCC: Integrating New Data into PracticeRichard S. Finn Geffen School of Medicine at UCLA

Co-hostEisaiCo.,Ltd.

MoS-9 7:308:20Room 6 23F3AChallenge ! BRAF as the driver gene opens up the future through Melanoma to NSCLCDriverBRAF

ChairsHisashi Uhara Department of Dermatology, Sapporo Medical University School of Medicine

Kazuhiko Nakagawa Department of Medical Oncology, Kindai University Faculty of Medicine

BRAF as the driver geneDriverBRAF

Seiji Yano Division of Medical Oncology, Kanazawa University Cancer Research Institute

The bridge between Melanoma and NSCLC Evidence and Clinical Practice

Yutaka Fujiwara Department of Experimental TherapeuticsDepartment of Thoracic Oncology, National Cancer Center Hospital


MoS-10 7:308:20Room 7 23F3BGene Panel to Whole Exome Sequence: Can we adapt this for cancer genomic testing?Whole Exome Sequence

Hiroshi Nishihara Genomics Unit, Keio Cancer Center, Keio University School of Medicine

Co-hostIlluminaK.K.


85

MoS-11 7:308:20Room 12 5F501Gastroenteropancreatic neuroendocrine tumor Delve into deeper! Seek for the optimal treatment strategy

ChairJunji Furuse Department of Medical Oncology, Kyorin University School of Medicine

Surgical treatment of GI-NET according to the progressionNET

Tsuyoshi Konishi Colorectal Division, Department of Gastroenterological Surgery, Cancer Institute Hospital of the Japanese Foundation for Cancer Research

Selecting best therapeutic options for patients with advanced GEP NETGEP NET

Masafumi Ikeda Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East


MoS-12 7:308:20Room 13 5F502ChairKenichi Ishizawa Department of Neurology, Hematology, metabolism, Endocrinology

and Diabetology, Yamagata University Faculty of Medicine

Risk management of Tumor lysis syndrome

Michihide Tokuhira Department of Hematology, Saitama Medical Center, Saitama Medical University

Co-hostSanofiK.K.


86

ÝÃ §ç·ÛÆ ÒÇï¬·ÛÆ Þ Çï¬·ÛÆ w] º ... · $p iptu &mj-jmmz+bqbo, , Ô å ææ...

Documents